ArticlePloS one2016
Taxa of the Nasal Microbiome Are Associated with Influenza-Specific IgA Response to Live Attenuated Influenza Vaccine.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 75 citations in OpenAlex.
- Pneumococcal colonization impairs mucosal immune responses to live attenuated influenza vaccine.JCI insight · 2021Trial
- Trial
- Insights into Microbiota-Vaccine Crosstalk in Humans: Mechanisms, Modulators, and Translational Horizons.Vaccines · 2026Review
- Respiratory Microbiome Remodeling in Aging: Implications for Immunosenescence and Therapeutic Intervention.Immune network · 2026Review
- Influenza pneumonia mice under different immune conditions: changes in pulmonary microbiota and metabolites.Microbiology spectrum · 2026Article
- Differences in Non-Pathogenic Lung-Colonizing Bacteria Among Patients with Different Types of Pneumonia: A Retrospective Study.Microorganisms · 2025Article
- A user's guide to designing efficient and safe mucosal vaccines: Challenges & potentials.Oxford open immunology · 2025Review
- Oral Pathogens' Substantial Burden on Cancer, Cardiovascular Diseases, Alzheimer's, Diabetes, and Other Systemic Diseases: A Public Health Crisis-A Comprehensive Review.Pathogens (Basel, Switzerland) · 2024Review
- The Effect ofMicroorganisms · 2023Article
- Unique microbial landscape in the human oropharynx during different types of acute respiratory tract infections.Microbiome · 2023Article
- Autoimmunity: A New Focus on Nasal Polyps.International journal of molecular sciences · 2023Review
- A Review on the Nasal Microbiome and Various Disease Conditions for Newer Approaches to Treatments.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2023Article
- Microbiota composition in the lower respiratory tract is associated with severity in patients with acute respiratory distress by influenza.Virology journal · 2023Article
- Article
- Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine.Cell reports. Medicine · 2022Article
- Factors Limiting the Translatability of Rodent Model-Based Intranasal Vaccine Research to Humans.AAPS PharmSciTech · 2022Review
- Microbiota in health and diseases.Signal transduction and targeted therapy · 2022Review
- Nasopharyngeal Bacterial Microbiota Composition and SARS-CoV-2 IgG Antibody Maintenance in Asymptomatic/Paucisymptomatic Subjects.Frontiers in cellular and infection microbiology · 2022Article
- Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms.Nature reviews. Immunology · 2022Review
- Lung Microbiome in Critically Ill Patients.Life (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Live attenuated influenza vaccine (LAIV) has demonstrated varying levels of efficacy against seasonal influenza; however, LAIV may be used as a tool to measure interactions between the human microbiome and a live, replicating virus. To increase our knowledge of this interaction, we measured changes to the nasal microbiome in subjects who received LAIV to determine if associations between influenza-specific IgA production and the nasal microbiome exist after immunization with a live virus vaccine. The anterior nares of 47 healthy subjects were swabbed pre- (Day 0) and post- (Days 7 and 28) LAIV administration, and nasal washes were conducted on Days 0 and 28. We performed next-generation sequencing on amplified 16s rRNA genes and measured mucosal influenza-specific IgA titers via enzyme-linked immunosorbent assay (ELISA). A significant increase in alpha diversity was identified (Observed, CHAO, and ACE) between Days 7 vs 0 (p-values = 0.017, 0.005, 0.005, respectively) and between Days 28 vs 0 (p-values = 0.054, 0.030, 0.050, respectively). Several significant associations between the presence of different microbial species, including Lactobacillus helveticus, Prevotella melaninogenica, Streptococcus infantis, Veillonella dispar, and Bacteroides ovatus, and influenza-specific H1 and H3 IgA antibody response were demonstrated. These data suggest that LAIV alters the nasal microbiome, allowing several less-abundant OTUs to establish a community niche. Additionally, specific alterations in the nasal microbiome are significantly associated with variations in influenza-specific IgA antibody production and could be clinically relevant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.